
MAN Yohimbine HCL 60 Caps


Yohimbine is an alkaloid with stimulant and aphrodisiac effects found naturally in Pausinystalia yohimbe (Yohimbe). According to several studies, oral yohimbine supplementation may actuate significant fat loss in athletes MAN Sports YOHIMBINE HCL is pharmaceutical grade. Combine MAN Sports YOHIMBINE HCl with SCORCH and/or VAPORIZE for maximum metabolism and fat loss.
As an adult dietary supplement take 1 to 2 servings daily. For best results combine MAN Sports Yohimbine HCL with SCORCH and/or VAPORIZE for improved metabolism and fat loss.
Supplement Facts:
Serving Size: 1 Capsule
Servings Per Container: 60
Amount Per Serving
Yohimbine HCL 3mg
MAN Yohimbine HCL Other Ingredients:
Rice Flour, Gelatin, Magnesium Stearate
KEEP OUT OF REACH OF CHILDREN. Not for use by individuals under the age of 18 or elderly. Consult a physician before using this or any dietary supplement. Do not use if pregnant, nursing or chronically ill. This product is not intended for individuals who are at risk or have been treated for digestive disorders, high blood pressure, heart disease, thyroid disease, depression or other psychiatric conditions, reoccurring headaches, spasms, has asthma or taking asthma medication. Do not use with alcohol or anti-depressants or MAO inhibitors.
Ostojic SM. Yohimbine: the effects on body composition and exercise performance in soccer players. Res Sports Med. 2006 Oct-Dec;14(4):289-99. doi: 10.1080/15438620600987106. PMID: 17214405.
https://pubmed.ncbi.nlm.nih.gov/17214405/
Zito G, Campbell B, Colquhoun R, et al. Proceedings of the Eleventh International Society of Sports Nutrition (ISSN) Conference and Expo. J Int Soc Sports Nutr. 2014;11(Suppl 1):P1-P51. Published 2014 Dec 1. doi:10.1186/1550-2783-11-s1-p1
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271572/
Akhondzadeh S, Amiri A, Bagheri AH. Efficacy and Safety of Oral Combination of Yohimbine and L-arginine (SX) for the Treatment of Erectile Dysfunction: a multicenter, randomized, double blind, placebo-controlled clinical trial. Iran J Psychiatry. 2010;5(1):1-3.